Angioedema News and Research

RSS

Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis.

mRNA COVID-19 vaccines may increase patients' concerns about side effects

Vivid photos of the red "COVID arm" rash and reports of facial swelling in patients who have received dermatological fillers after Pfizer-BioNTech or Moderna vaccination for COVID-19 may increase patients' concerns about mRNA vaccine side effects and contribute to vaccine hesitancy.

23 Jun 2021

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

In a recently published article in the journal Frontiers in Immunology, scientists have reviewed the existing literature on antiviral and anti-inflammatory efficacy of resveratrol-based inhaled formulations in preventing SARS-CoV-2 infection and reducing COVID-19 severity.

9 Jun 2021

FDA grants accelerated approval for first-of-its-kind Alzheimer's treatment

Today, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer's, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

7 Jun 2021

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

The heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin-converting enzyme (ACE) inhibitor proven effective in improving survival following heart attacks.

17 May 2021

FDA approves new indication for drug to treat pediatric NDO patients

Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.

25 Mar 2021

Innate immune system overreacts in patients with severe COVID-19

In patients with severe COVID-19, the innate immune system overreacts. This overreaction may underlie the formation of blood clots (thrombi) and deterioration in oxygen saturation that affect the patients.

23 Feb 2021

Providing personalized care for bleeding disorders

An interview with Dr. Carmen Escuriola-Ettingshausen MD, Mörfelden-Walldorf, Germany on providing personalized care for bleeding disorders.

From Takeda 21 Sep 2020

Providing personalized care for bleeding disorders

An interview with Dr. Carmen Escuriola-Ettingshausen MD, Mörfelden-Walldorf, Germany on providing personalized care for bleeding disorders.

From Takeda 21 Sep 2020

COVID-19 patients with hypoxia respond positively to a treatment, study shows

Covid-19 patients with hypoxia respond positively to icatibant treatment, Radboud university medical center researchers wrote in JAMA Network Open.

19 Aug 2020

Computational analyses suggest new pathway for inflammatory response to SARS-CoV-2

Analyses of lung fluid cells from COVID-19 patients conducted on the nation's fastest supercomputer point to gene expression patterns that may explain the runaway symptoms produced by the body's response to SARS-CoV-2.

28 Jul 2020

C-Path's Transplant Therapeutics Consortium receives positive FDA response for its Letter of Intent

Critical Path Institute announced today that its Transplant Therapeutics Consortium has received a positive response to its Letter of Intent from the U.S. Food and Drug Administration detailing the decision to accept the Composite Biomarker Panel (iBox Scoring System) into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program.

17 Jun 2020

CSL Behring and Seattle Children's partner to develop gene therapies for primary immunodeficiency diseases

Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.

2 Jun 2020

Radboudumc researchers find essential mechanism in the disease process of COVID-19

Researchers at the Radboud University Medical Center seem to have found an essential mechanism in the disease process of COVID-19, which has so far been overlooked.

29 Apr 2020

New, previously unknown form of familial cold urticaria discovered

Skin rash combined with head and joint pain: these are the symptoms which patients with familial (hereditary) cold urticaria develop when exposed to temperatures below 15 °C.

27 Apr 2020

Treatments for rare diseases affecting children are increasing, study suggests

The number of treatments for rare diseases affecting children has increased, a new study suggests. But federal incentives intended to encourage drug development for rare conditions are being used more often to expand the use of existing drugs rather than for creating new ones.

3 Mar 2020

ARNI therapy trial misses target in heart failure, may have selective benefit only

Heart failure with preserved ejection fraction (HFpEF) is a common condition, affecting millions of people and resulting in significant illness and death. No effective treatments have been developed for this condition.

2 Sep 2019

FDA grants approval for generic versions of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as an adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury.

22 Jul 2019

Study provides new understanding of mysterious 'hereditary swelling'

An upper arm that swells to twice its normal size. A stomach that inexplicably swells up causing colic pain, vomiting or diarrhea. Or a life-threatening variant with severe swelling of the face, lips, tongue and larynx, bringing the risk of obstructed airways and death by suffocation.

11 Dec 2018

New antibody can reduce swelling attacks in patients with hereditary angioedema

Patients with hereditary angioedema experience recurrent and sometimes life-threatening swelling attacks. Researchers from Charité - Universitätsmedizin Berlin have tested an antibody capable of reducing the frequency of these swelling attacks by more than 90 percent.

28 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Angioedema News and Research

Further Reading

mRNA COVID-19 vaccines may increase patients' concerns about side effects

Researchers review the therapeutic potential of resveratrol nasal formulations in COVID-19

FDA grants accelerated approval for first-of-its-kind Alzheimer's treatment

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

FDA approves new indication for drug to treat pediatric NDO patients

Innate immune system overreacts in patients with severe COVID-19

Providing personalized care for bleeding disorders

Providing personalized care for bleeding disorders

COVID-19 patients with hypoxia respond positively to a treatment, study shows

Computational analyses suggest new pathway for inflammatory response to SARS-CoV-2

C-Path's Transplant Therapeutics Consortium receives positive FDA response for its Letter of Intent

CSL Behring and Seattle Children's partner to develop gene therapies for primary immunodeficiency diseases

Radboudumc researchers find essential mechanism in the disease process of COVID-19

New, previously unknown form of familial cold urticaria discovered

Treatments for rare diseases affecting children are increasing, study suggests

ARNI therapy trial misses target in heart failure, may have selective benefit only

FDA grants approval for generic versions of Lyrica

Study provides new understanding of mysterious 'hereditary swelling'

New antibody can reduce swelling attacks in patients with hereditary angioedema

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News